Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches.

ABSTRACT: People with coronavirus disease (COVID-19) might have several risk factors for delirium, which could in turn notably worsen the prognosis. Although pharmacological approaches for delirium are debated, haloperidol and other first-generation antipsychotics are frequently employed, particularly for hyperactive presentations. However, the use of these conventional treatments could be limited in people with COVID-19, due to the underlying medical condition and the risk of drug-drug interactions with anti-COVID treatments. On these premises, we carried out a rapid review in order to identify possible alternative medications for this particular population. By searching PubMed and the Cochrane Library, we selected the most updated systematic reviews of randomised trials on the pharmacological trea

SUBMITTER: Ostuzzi G 

PROVIDER: S-EPMC7372613 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature